Sanofi buys into NeuroVive's cardio drug in Korea

Sanofi ($SNY) is betting on the promise of NeuroVive Pharmaceutical's top prospect, buying the South Korean rights to the biotech's Phase III cardiovascular drug. Under the deal, Sanofi is paying an undisclosed upfront payment and promising cash milestones to co-develop CicloMulsion, a drug designed to treat injuries that result from post-heart attack reperfusion. Sanofi will handle the Korean launch, promotion and sale of CicloMulsion if it wins approval, paying its partner an unspecified royalty. More

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.